Novo Nordisk A/S vs iShares TIPS Bond ETF — how do they compare? Novo Nordisk A/S trades at $44.89 (market cap $200.69B), while iShares TIPS Bond ETF trades at $106.82. The key difference: Novo Nordisk A/S pays a 3.98% dividend while iShares TIPS Bond ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.
| NVO | TIP | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Fixed Income |
52-Week High | $63.98 | $112.20 |
52-Week Low | $35.29 | $106.77 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
TIP trades at $107.05 with minimal daily movement (+0.07%), showing stability amid broader market volatility. Technical indicators signal a bearish trend with moving averages and overall momentum favoring sellers. The company has announced upcoming dividends totaling $1.84 per share for H2-2026, providing income appeal. Recent news highlights Treasury market volatility and inflation concerns that may impact bond-related equities.
The stock faces headwinds from bearish technical momentum and macroeconomic uncertainty around interest rates. Dividend payments offer some support, but limited fundamental data availability requires careful monitoring of upcoming financial disclosures for clearer valuation assessment.
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.
Read more on TIP →